Prolyl Oligopeptidase, Inositol Phosphate Signalling and Lithium Sensitivity by Harwood, Adrian J
  CNS & Neurological Disorders - Drug Targets, 2011, 10, 333-339 333 
 
  1871-5273/11 $58.00+.00  © 2011 Bentham Science Publishers 
Prolyl Oligopeptidase, Inositol Phosphate Signalling and Lithium 
Sensitivity 
Adrian J. Harwood
* 
School of Biosciences, Cardiff University, Museum Ave, Cardiff, CF10 3AX, UK 
Abstract: Inhibition of prolyl oligopeptidase (PO) elevates inositol phosphate (IP) signalling and reduces cell sensitivity to lithium (Li
+). 
This review discusses recent evidence that shows PO acts via the multiple inositol polyphosphate phosphatase (MIPP) to regulate gene 
expression. As a consequence, PO inhibition causes both a transient, rapid increase in I(1,4,5)P3 and a long-term elevation of IP 
signalling. This pathway is evolutionary conserved, being present in both the social amoeba Dictyostelium and human cell systems, and 
has potential implications for mental health. 
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INTRODUCTION 
  An intriguing aspect of prolyl oligopeptidase (PO) biology is its 
relationship with bipolar mood disorder and lithium (Li
+) 
sensitivity. Bipolar mood disorder, also know as manic-depression, 
is a prevalent mental illness with a significant socio-economic 
impact. The biological causes of this major mental disorder remain 
unknown and, despite a strong genetic evidence for predisposition, 
there are currently no universally agreed consensus candidate genes 
that confer risk. Li
+ is the most commonly used mood stabilizer 
used in the treatment of bipolar mood disorder and is particularly 
useful as a prophylactic, suppressing the re-occurrence of the 
illness. However, Li
+ is taken in high doses, has side-effects and is 
not effective in all cases. Although a number of enzyme targets 
have been well characterised, how Li
+ treatment mediates its action 
also remains unknown. This review describes recent results 
investigating how PO modulates cell sensitivity to Li
+, and how this 
may relate to the treatment and molecular origins of bipolar mood 
disorder. 
BIOCHEMICAL TARGETS OF LITHIUM 
Inositol Phosphate (IP) Signalling 
  The first enzyme target of Li
+ identified was inositol 
monophosphatase (IMPase) [1].
  This dephosphorylates inositol 
monophosphate to release myo-inositol, which is then transferred to 
diacyl glycerol to form phosphatidyl inositol (PI). This is then 
further phosphorylated on the inositol ring to create a range of lipid 
molecules with various signalling functions (Fig. 1A). The two 
most studied are PI(4,5)P2 and PI(3,4,5)P3 (PIP3) [2, 3] although 
other lipids, such as PI(3)P and PI(3,4)P2 are important in 
membrane trafficking in the cell [4]. Inositol monophosphate is 
formed by dephosphorylation of the soluble inositol phosphate, 
I(1,4,5)P3 (IP3) by specific IP3 5’phosphatases to I(1,4)P2 and then 
further dephosphorylation by inositol 1-polyphosphate phosphatase 
(IPP), a second lithium sensitive enzyme with a protein structure 
closely related to IMPase [5] (Fig. 1A). Alternatively myo-inositol 
is synthesised de novo by isomerisation of glucose-6-phosphate 
through the action of inositol synthase (Ino1) [6]. As a consequence 
cellular synthesis of myo-inositol is sensitive to Li
+. This has the 
potential to deplete the cellular concentration of inositol, however 
in many cases inositol can be taken up from the environment via 
transporter proteins in the membrane [6]. A significant change in  
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IP signalling due to inositol depletion presumably occurs in cells 
where environmental inositol is low, however in some conditions 
Li
+ and other mood stabilizers may also lower inositol up-take 
potentially enhancing their effects [7]. 
 PI(4,5)P2 is a substrate for the enzyme phospholipase C (PLC), 
which, following cell stimulation, releases the second messenger, 
IP3. This binds the IP3 receptor on the endoplasmic reticulum to 
release Ca
2+ from its intracellular store [8]. This transient elevation 
of intracellular Ca
2+ elicits a range of cellular processes, including 
cell motility, cell survival and neurotransmitter release. Li
+ is well 
documented in lowering IP3 and cellular Ca
2+ levels in cultured 
cells, however its effects on the brain tissue can vary on cell type or 
species [9], and may reflect variation of indirect effects though 
feedback from downstream processes, such as glutamate uptake 
[10]. 
  However, there are other inositol containing signal molecules in 
the cell, and a particular interesting molecule is the phospholipid, 
PIP3. This is synthesised from PI(4,5)P2 following stimulation of 
class 1 PI3 kinases (PI3Ks). PIP3 is also an important cell regulator 
being involved in many processes including cell growth, survival 
and chemotaxis [11]. Once generated on the plasma membrane PIP3 
acts as a binding site for PH domain proteins, bringing them in 
contact with activator and effector proteins. For example, PIP3 
promotes contact between the protein kinases  and PKB (also 
known as AKT) allowing  phosphorylation and activation of PKB 
[12, 13]. 
  Surprisingly, until recently the notion that PIP3  could be 
sensitive to Li
+ had not been tested. However, a direct effect of Li
+ 
on PIP3 has recently been shown in the social amoeba Dictyostelium 
[14].  Dictyostelium is a single celled eukaryote with a close 
phylogenetic relationship to the animals. It grows as unicellular 
amoeba, but when depleted of nutrients enters a developmental 
program to form a multicellular fruiting body [15] (Fig. 2A). This is 
a highly differentiated structure comprising a small number of cell 
types. The majority of cells differentiate into spore cells, which are 
resistant to environmental stress, but germinate to release amoeba 
when conditions favour cell growth. The remaining cell types form 
the fruiting body structure that supports the spore head. Early 
Dictyostelium development is dependent on chemotaxis towards 
extracellular pulses of cAMP, which brings cells together into the 
multicellular aggregation. PIP3 based signalling is an important part 
of this process and is sensitive to Li
+ (Fig. 2A). 
 Li
+ treatment of Dictyostelium cells has a specific effect on 
cAMP-dependent chemotaxis, reducing cell speed and path 
linearity, but having only a minor effect on the ability to sense the 
direction of the cAMP source (Fig. 2B, C). Exactly the same effects 
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treated with the PI3K inhibitor LY294002 [16, 17]. Measuring 
either absolute PIP3 concentrations, phosphorylation of PKB or 
translocation of a GFP-fused PH domain showed that Li
+ indeed 
suppresses PIP3 synthesis following cAMP stimulation [14]. 
Similarly, PIP3 signalling is also suppressed in the human HL60 
neutrophil-like cell line following stimulation with the ligand 
fMLP. Consistent with inositol depletion, over-expression of 
IMPase in Dictyostelium cells reverses the effects of Li
+. 
  Interestingly, in the absence of Li
+, IMPase over-expressing 
cells show higher levels of stimulated PIP3 than wild type cells, 
indicating that inositol synthesis is limiting for cell signalling. This 
comes as a surprise as the steady-state concentration of PI(4,5)P2 is 
200 times that of PIP3 and is unaltered by Li
+ treatment. However, 
when newly synthesised PI(4,5)P2 is measured, Li
+ causes a 60% 
decrease that mirrors that of PIP3. Over-expression of IMPase 
reverses the effect of Li
+, whereas PI(4,5)P2 concentrations are 
higher than wild type cells in the absence of Li
+ [14]. These results 
indicate that there is a rapidly synthesised, but small, pool of 
PI(4,5)P2 that is sensitive to Li
+ treatment. 
Glycogen Synthase Kinase-3 (GSK-3) 
  The second major Li
+ target is GSK-3, a highly conserved 
protein kinase which is involved in a plethora of cellular processes, 
including differentiation and development, growth and survival, 
chemotaxis and metabolism, as well as controlling glycogen 
synthesis [18]. As a consequence, mis-regulation of GSK-3 has 
been associated with a number of clinical conditions, such as 
diabetes, oncogenesis and neurodegeneration. Li
+ inhibits GSK-3 
with a Ki of 2.0 mM for the GSK-3 isoform and an IC50 of 3.5 
mM for the GSK-3 isoform [19, 20]. Biochemical analysis 
showed that maximal GSK-3 activity requires high concentrations 
(~20 mM) of Mg
2+, and that this Mg
2+ dependency is competed by 
Li
+. As Li
+ is a non-competitive inhibitor with regard to its 
substrate and ATP, it would appear that the Li
+ sensitivity of GSK-
3 is via  a Mg
2+-binding site that is distinct from the Mg-ATP 
binding site present in all other kinases [21]. Consistent with this 
notion, GSK-3 is the only known Li
+ sensitive protein kinase. 
Other Li
+ Targets 
  A third enzyme target of Li
+ is phosphoglucomutase (PGM) 
[22]. This enzyme reversibly converts glucose-1-phosphate to 
glucose-6-phosphate, and is inhibited in the same concentration 
range of Li
+ as IMPase and GSK-3. Interestingly, GSK-3 is a 
negative regulator of glycogen synthase, reducing glucose 
conversion to glycogen, and hence Li
+ inhibition of GSK-3 would 
lead to decreased glucose. As glucose-6-phosphate is the substrate 
for Ino1, inositol synthesis would be expected to be sensitive to 
altered activity of both PGM and GSK-3. This suggests that Li
+ 
treatment could potentially be able to reduce inositol biosynthesis 
via simultaneously inhibiting all three enzyme targets (Fig. 1A). 
  In contrast, Li
+ has also been suggested to have a non-
enzymatic action by disruption of a protein complex containing -
arrestin2, the phosphatase PP2A and PKB [23]. The complex forms 
following dopamine binding to its D2 receptors, leading to 
inactivation of PKB due to dephosphorylation by PP2A. Li
+ 
treatment releases PKB from the complex increasing its activity, 
and in turn phosphorylating and inactivating GSK-3 (Fig. 1B). 
Exactly how this works is unclear, and in fact it has frequently been 
reported that inhibition of GSK-3 feeds back to elevate its own 
phosphorylation via PKB [24-26], so it remains to be conclusively 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Cellular targets of Li
+. (A) Inositol phosphate (IP) biosynthesis and signalling. Inositol is recycled from I(1,4,5)P3 (IP3) by inositol polyphosphate 1-
phosphatase (IPP) and inositol monophosphatase (IMPase). It is also synthesised from glucose-6-phosphate via inositol synthase to inositol monophosphate 
(IP). Glucose is released from glycogen in the form of glucose-1-phosphate, which is then converted to glucose-6-phosphate by phosphoglucomutase (PGM). 
Glucose is incorporated into glycogen, via glucose-1-phospahte and UDP-glucose intermediates, by Glycogen synthase (GS), which in turn is inhibited by 
glycogen synthase kinase 3 (GSK3). Inositol is incorporated into PI(4,5)P2 (PIP2) by PI synthase, PI4 kinases and PI5 kinases. Upon cell stimulation, PIP2 is 
either converted to PIP3 via activation of PI3 kinase or is hydrolysed to release IP3, which in turn stimulates calcium release from intracellular stores. PIP3 is 
dephosphorylated to PIP2 by PTEN, which requires PIP2 to associate with the plasma membrane. Li
+ inhibits IMPase, IPP, PGM and GSK3, whereas valproic 
acid (VPA) inhibits inositol synthase. All of these targets have the potential to reduce myo-inositol. GSK-3 has many other cellular targets (not shown). (B) 
Dopamine and regulation of PKB. PIP3 stimulates activation of the protein kinase, PKB, whereas dopamine suppresses PKB activity by formation of a 
complex between -arrestin2, PKB and the phosphatase PP2A. Li
+ causes the -arrestin2 complex to disassemble, increasing PKB activity, which then 
phosphorylates and inactivates GSK-3. 
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established whether this mechanism is truly independent of GSK-3 
inhibition. 
LI
+ SENSITIVITY MUTANTS OF DICTYOSTELIUM 
 Li
+ has a variety of effects on Dictyostelium development, 
which can be distinguished by dose and timing. In addition to its 
effect on chemotaxis and PIP3 signalling, lower concentrations of 
Li
+ cause altered multicellular development, where the one 
population of stalk cells enlarges at the expense of the spore head 
[27]. This is due to a change in cell fate during early multicellular 
development due to blocking the regulatory effects of cAMP on cell 
differentiation, and closely resembles the phenotype seen when the 
Dictyostelium GSK-3 gene is mutated [28]. GSK-3 is also required 
at the very onset of Dictyostelium development and GSK-3 mutants 
are incapable of both cAMP signalling and chemotaxis [29] (Fig. 
2A). However loss of GSK-3 activity has very different effects 
from the chemotaxis deficit that arises due to suppression of PIP3 
signalling [14] and studies in Dictyostelium offer an easy means of 
distinguishing between different lithium targets on the basis of 
altered cell behaviour, something that is often difficult with other 
cell systems. 
  Using resistance to Li
+ as a phenotype, a series of mutants with 
reduced sensitivity were isolated; these were referred to as lis 
mutants [27] (Fig. 2C). The first mutant to be fully characterised 
was lisA. This mutant arose from an insertion into the Dictyostelium 
PO gene, DpoA, and lacked all PO activity. Importantly, no 
suppression of the GSK-3 mutant phenotype was seen when GSK-3 
and DpoA mutations were combined. However, loss of dpoA or 
treatment with PO inhibitors elevates IP3, suggesting that PO is a 
modulator of IP signalling [27]. 
 
 
PO AND MULTIPLE INOSITOL POLYPHOSPHATE 
PHOSPHATASE (MIPP) 
  Given the known action of PO on neuropeptides and peptide 
hormones [30], initial thoughts were that decreased extracellular 
peptide signals could lead to higher IP3 through chronic PLC 
stimulation. However a number of observations argue against this 
possibility. First, there is no evidence for increased PLC activity 
following loss or inhibition of DpoA [27]. Second, phenotypes of 
PLC and IP3 receptor mutants do not match the PO phenotype [31, 
32]. Finally, PO activity is cytosolic and would not directly act on 
an extracellular signal peptide [27]. Consistent with this, 
experiments of mixing wild type and DpoA mutant cells 
demonstrated that the signalling defect is cell non-autonomous [27]. 
If IP3 is not generated by activation of PLC, could it be due to 
decreased IP3 breakdown by an IP3 5’ phosphatase? In fact, 5’ 
phosphatase activity is increased rather than decreased in DpoA 
mutant cells, arguing that the production of IP3 is actually higher 
than measured by steady state levels of IP3 in the mutant [27]. 
These observations exclude PLC and 5’phosphatase activities as the 
source of IP3. 
  Multiple inositol polyphosphate phosphatase (MIPP) is a 
histidine acid phosphatase that dephosphorylates the higher order 
inositol phosphate IP6 to IP3 via IP5 and IP4 intermediates [33-35]. 
It also can dephosphorylate 2,3-diphosphoglycerate (DPG) and 
offering a new addition to the Rapport-Lubering shunt, a side 
branch of glycolysis [36]. Without 2,3 DPG, oxygen would bind too 
tightly to haemoglobin [37, 38], and as MIPP activity is sensitive to 
changes in over a pH range of 7.0-7.8, it is ideally suited to regulate 
oxygen binding in response to decreased carbon dioxide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Li
+ sensitivity of Dictyostelium of development and chemotaxis. (A) Dictyostelium developmental cycle. Individual cells enter development upon 
starvation and aggregate via chemotaxis to form a mound of cells. The mound undergoes a series of morphogenetic changes to give rise to the fruiting body. 
When dispersed, spores germinate and grow as amoebae. There are a number of Li
+-sensitive stages of Dictyostelium development. The Li
+-sensitive protein 
kinase, GSK-3, regulates cell fate during multicellular development and acts at the beginning of development as a permissive signal to allow chemotaxis and 
cell signaling (grey arrow). During aggregation, Li
+ has a distinct role mediating inositol phosphate signaling and is required for PIP3 signalling. (B) Li
+ alters 
chemotaxis. Photographs of wild type cells treated with LiCl or NaCl (control) during chemotaxis towards cAMP. (C) Tracks of representative cells migrating 
towards a cAMP source. Wild type cells treated with 7 mM Li
+ or Na
+ (control). Li
+ treated cells move towards the cAMP source but move with half the speed 
and turn more than control cells. Increased expression of IMPase or loss of DpoA suppresses this effect; where as loss of MIPP enhances this effect. Based on 
original data published in [35]. 336      CNS & Neurological Disorders - Drug Targets, 2011, Vol. 10, No. 3  Adrian J. Harwood 
  Mutants lacking DpoA have decreased MIPP activity, leading 
to increased IP3 [27], whereas those lacking the MIPP gene do not 
increase IP3 following PO inhibition [35]. This suggests that DpoA 
acts to represses MIPP activity altering the cellular IP3 
concentrations. Consistent with these observations, MIPP mutants 
are Li
+ hypersensitive, showing a significantly stronger effect of Li
+ 
on chemotaxis (Fig. 2C). Mutants that combine both DpoA and 
MIPP mutations are Li
+ hypersensitive, not resistant, placing MIPP 
genetically downstream of DpoA [35]. 
  The DpoA-MIPP interaction can be reconstituted in a cell free 
extract using recombinant PO and a semi-purified MIPP enzyme 
made from cells over-expressing MIPP. Addition of PO inhibits 
MIPP activity, and can be reversed by inclusion of a PO inhibitor. 
How this is actually achieved is unclear. Western blotting shows no 
increase in mobility of the MIPP enzyme, indicating that it is not 
directly cleaved. As MIPP is prepared as a membrane fraction, it 
would seem likely that direct target of PO is a co-purified peptide, 
whose current identity is unknown. In whole cells, IP3 
concentrations rise by 30 minutes and then drop to basal values 
within an hour. Both in vitro and in vivo assays therefore indicate a 
rapid change of MIPP activity following loss of PO activity. 
PO AND GENE REGULATION 
  Although tempting to assume that the rise in IP3 following PO 
inhibition directly leads to Li
+ resistance, there are a number of 
observations that argue that this is not the case [35]. First, there is 
the theoretical argument that as Li
+ is an uncompetitive inhibitor of 
IMPase, elevating the concentration of its inositol phosphate 
substrates should enhance rather than alleviate Li
+ inhibition [39]. 
Only increased IMPase gene expression would confer Li
+ 
resistance, as seen for Li
+ inhibition of PIP3. Second, in contrast to 
DpoA, genetic manipulation of MIPP, either by gene disruption or 
over-expression, has no long-term direct effect on IP3 
concentration, however both have Li
+ hypersensitive phenotypes. 
This argues that whilst DpoA mediated changes in MIPP activity 
lead to transient changes in IP3 levels, it is not the end point of the 
signal pathway, but in fact lies en route to more long-term changes 
in cell behaviour. 
  Further investigation showed that PO inhibition leads to 
decreased expression of the genes encoding inositol synthesis 
(IMPase and Ino1) and inositol recycling (IPP and IP3 
5’phosphatase genes) [35]. Elevation of 5’phosphatase gene 
expression fits the observation that DpoA mutants has decreased 
5’phosphatase activity [27], and increased IMPase expression 
explains how cells become Li
+ resistant, as consistent with an 
uncompetitive mode of inhibition by increasing enzyme rather than 
substrate concentration. DpoA mediated gene expression is 
dependent on MIPP, as PO inhibitors no longer elevate gene 
expression in a MIPP mutant strain. 
  The exact mechanism leading to gene expression changes is not 
fully worked out, however there are some strong pointers to other 
elements of the signalling pathway [35]. Over-expression of MIPP1 
both causes Li
+ hypersensitivity and lowers concentrations of 
I(1,3,4,5,6)P5 and IP6. I(1,3,4,5,6)P5 has previously been shown to 
regulate ino1 and pho gene expression in yeast [40], and has been 
found in mammalian cells to mediate some aspects of signalling via 
the extracellular protein ligand Wnt [41]. Consistent with the 
involvement of I(1,3,4,5,6)P5 or a related higher order inositol 
phosphate, over-expression of the IP3 kinases, inositol 
polyphosphate multikinase and inositol 1,3,4-triphosphate 5/6 
kinase, which produce I(1,3,4,5,6)P5, elevate Ino1 and IMPase gene 
expression and confers Li
+ resistance [35]. Furthermore, 
I(1,3,4,5,6)P5 and IP6 regulate ino1 gene expression in yeast by 
regulation of chromatin re-modelling via  the ATP-dependent re-
modellers Swi/SNF2 and Ino80 [40, 42]. These observations 
suggest that DpoA and MIPP may in fact act within a gene 
regulatory network that also involves IP5 and IP6 signalling and 
chromatin remodelling. 
PO SIGNALLING IN MAMMALIAN CELLS 
 These  Dictyostelium observations reveal the existence of a 
novel signalling pathway that is mediated via changes in PO and 
MIPP activity, however, is this a conserved pathway? A number of 
observations link PO activity to changes in IP signalling and Li
+ 
sensitivity in mammalian systems. 
  In rats and humans, PO activity and expression has been found 
throughout the tissues of the body, but it is enriched in the brain. 
Looking at the brain in more detail, it is clear that there is 
differential enrichment within the brain, so that higher PO levels are 
seen in hippocampal CA1 pyramidal cells, cortical interneurons and 
pyramidal cells, striatal spiny neurons, cells in the thalamus and 
cerebllar Purkinje cells [43]. Interestingly, in many of these cells 
PO expression colocalizes with the IP3 receptor type 1 protein 
expression, suggesting a regulatory relationship between PO and 
IP3 signalling [44, 45]. 
  In astroglioma cells, treatment with PO inhibitors or PO-
specific siRNA elevates IP3 signalling in response to Substance P 
[46]. In primary neurons, Li
+ mediated growth cone spreading is 
reversed by either addition of myo-inositol or PO inhibition [47]. 
Finally, in COS-7 cells, the cellular process of macro-autophagy 
and clearance of Huntingtin and -synuclein protein aggregates is 
stimulated by Li
+ through an inositol-depletion mechanism [48]. 
Again Li
+ action on these processes is suppressed by PO inhibition. 
  In addition, PO inhibitor treatment of HEK293 cells leads to 
decreased expression of the human homologues of Ino1 (ISYNA1) 
and IMPase (IMPA1 and IMPA2). This gene regulatory effect is 
suppressed by MIPP1 specific siRNAs [35]. These results 
demonstrate a conserved relationship between PO activity and gene 
expression; it is currently unknown whether altered I(1,3,4,5,6)P5, 
IP6 or chromatin re-modelling is also required for this signalling 
pathway. 
 In  Dictyostelium, DpoA expression and PO activity is 
developmentally regulated, being significantly up-regulated just 
prior to the formation of multicellularity [35]. It is not known what 
induces these changes. In contrast, recent results in SH-SY5Y 
neuroblastoma cells demonstrate PO expression and activity is up-
regulated following retinoic acid induction of cell differentiation 
[49]. Interestingly, PO activity is also required for gene expression 
in this system. However in this case there is neither up-regulation of 
genes involved with inositol biosynthesis, nor long-term changes in 
IP3 concentration. This suggests that PO may also mediate gene 
regulation in alternative signalling pathways to that modulating 
inositol biosynthesis. 
BIPOLAR SUSCEPTIBILITY GENES AND ENVIRON-
MENTAL RISK 
  What insights do these observations offer into the origins of 
bipolar mood disorder? In addition to Li
+, at least two other mood 
stabilizers, valproic acid (VPA) and carbamazepine (CBZ), alter 
neuronal cell behaviour in the same way as Li
+, and again can be 
reversed by either addition of myo-inositol or PO inhibition [47]. 
Similarly, VPA and CBZ also induce macro-autophagy and protein 
aggregate clearance, and again these effects are reversed by PO 
inhibition [48]. The cellular relationship between mood stabilizers 
and PO therefore appears to reach beyond simply the effects of Li
+, 
but has inositol phosphate signalling in common. 
  Altered PO activity has previously been linked to mental 
disorders. PO activity is decreased in schizophrenia patients and 
decreased in depression [50, 51]. In manic phase patients prior to 
treatment, plasma PO activity is decreased, but then reduced to 
below that of control patients following mood stabilizer treatment 
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took into account possible influences of a second oligopeptidase 
known as ZIP, although failing to see a significant increase in 
schizophrenia patients, again observed a decrease in bipolar patients 
[52]. Reduced PO activity would be expected to lead to decreased 
IMPase expression, which could be suppressed by Li
+ treatment. 
  The cause of decreased PO activity is unknown, however high 
doses of the cytokine IFN- in patients undergoing immunotherapy 
have been associated with lowered serum PO activity; it has been 
suggested that this is associated with symptoms of depression [53]. 
Mood disorders have previously been associated with an altered the 
inflammatory response and bipolar disorder patients have altered 
expression of genes associated with the pro-inflammatory response 
[54]. 
  Looking at the genes regulated by PO in HEK293 cells, it is 
notable that IMPA2 has previously been associated with bipolar 
mood disorder. Elevated IMPA2 expression has been reported in 
post-mortem patient brains [55]. This corresponds to the presence 
of a specific set of IMPA2 single nucleotide polymorphisms (SNPs) 
that associates with increased risk of developing bipolar disorder. 
These SNPs lie within the IMPA2 gene promoter and have been 
suggested result in decreased gene expression [55-57]; however 
further analysis is required to verify this link. 
  On the other hand, SNP analysis has failed to find a significant 
association of PO alleles and risk of bipolar disorder [58]. One 
interesting possibility is that PO lies at the intersection between 
environmental and genetic risk factors, with increased risk arising 
from inherited changes in gene promoter activity, such as suggested 
for IMPA2, in combination with environmentally induced changes 
in PO activity (Fig. 3). One scenario, for example, could arise if an 
environmentally induced-response, perhaps via  IFN-, lead to 
decreased PO activity and increased IMPA1 and ISYNA1 gene 
expression. This would interact with aberrant regulation of the 
IMPA2 promoter to cause substantial elevation of inositol 
biosynthesis and over-active IP signalling, which in turn could be 
suppressed by Li
+ or other mood stabilizers. Such enhanced 
signalling is seen in Dictyostelium when both the IMPase and Ino1 
genes are over-expressed [35]. This causes abnormally high cell 
motility speed that is then suppressed by Li
+. 
CONCLUSIONS 
  PO interacts with a novel intracellular signalling pathway, 
which regulates gene expression. This pathway requires the enzyme 
MIPP, which acts to regulate I(1,3,4,5,6)P5 and IP6, and regulates 
gene expression. IP3 is both decreased transiently following PO 
inhibition through decreased MIPP activity, and in the long term via 
decreased gene expression. This signalling pathway appears to be 
conserved in human cells, and has a number of characteristics that 
associate with observations on mental disorders. However, further 
work investigating the action of PO in model systems, as well as 
more genetic studies, will be required to establish the validity of 
these associations. 
ACKNOWLEDGEMENTS 
  AJH is grateful for support from the Wellcome Trust and a 
BBSRC Committee studentship. 
ABBREVIATIONS 
cAMP =  Cyclic  adenosine  monophosphate 
DPG =  Diphosphoglycerate 
GSK-3 =  Glycogen  synthase  kinase-3 
IMPase =  Inositol  monophosphatase 
Ino1 =  Inositol  synthase 
IP =  Inositol  phosphate 
MIPP  =  Multiple inositol polyphosphate phosphatase 
PGM =  Phosphoglucomutase 
PI =  Phosphatidyl  inositol 
PI(n,n,n)Px  =  Phosphatidyl phosphate, where n = position of  
     phosphate and x = number of phosphates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). A gene regulatory network modulates inositol phosphate signalling. Human PO regulates expression of the IMPA1, IMPA2 and ISYNA1 genes 
via control of MIPP. This gene regulatory network is discrete from ligand-stimulated regulation of IP3 and PIP3 signalling, and modulates long-term changes in 
inositol phosphate signalling. Altered PO activity and IMPA2 gene expression have been observed in bipolar disorder patients, and may embody inputs from 
environmental and genetic risk factors respectively. 
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PI3K =  Phosphatidyl  3-kinase 
PLC =  Phosopholipase  C; 
PO =  Prolyl  oligopeptidase; 
SNP  =  Single nucleotide polymorphism 
VPA =  Valproic  acid 
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